Zimmer Biomet (ZBH) is one of the leading providers of hip implants in the United States, with approximately 31% market share. That’s almost the same as Johnson & Johnson’s (JNJ) market share.

Zimmer Biomet will phase out sales of its CPT Hip System by December due to concerns about the risk of thigh bone fractures, the Food and Drug Administration said in a Tuesday notice. Despite ...

"Zimmer's belated suspension of sales of its defective product was too little, too late for Mr. Nunn and countless other patients who needed well-made artificial hip implants to restore their ...

The Food and Drug Administration said hip replacement surgeries that use Zimmer Biomet's CPT Hip System result in a higher risk of thigh bone fracture. The agency on Tuesday said recent research ...